发布求助
文献互助 智能选刊 最新文献

[Rinsho ketsueki] The Japanese journal of clinical hematology最新文献

筛选
英文 中文
[Molecular mechanisms of pediatric intractable leukemia]. [儿童难治性白血病的分子机制]。
[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2023-01-01 DOI: 10.11406/rinketsu.64.810
Junko Takita
{"title":"[Molecular mechanisms of pediatric intractable leukemia].","authors":"Junko Takita","doi":"10.11406/rinketsu.64.810","DOIUrl":"https://doi.org/10.11406/rinketsu.64.810","url":null,"abstract":"<p><p>Recent advances in intensive treatment strategies have resulted in an overall treatment rate of approximately 70% for pediatric cancers. The most notable improvement in clinical outcomes has been observed for acute lymphocytic leukemia, with the cure rate increasing from approximately 10% 50 years ago to 90% at present. However, relapsed and refractory cases of childhood leukemia continue to have a poor prognosis, and there is no standard treatment strategy for many cases. Moreover, even in cases with favorable outcomes, growth retardation and endocrine disorders are major complications. To improve the cure rate of pediatric cancers, we have focused on the molecular mechanisms of leukemia, the most common type of pediatric cancer. In this symposium, recent findings on T-cell acute lymphocytic leukemia will be outlined.</p>","PeriodicalId":6352,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"64 8","pages":"810-815"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10181327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Diagnosis and treatment of adult patients with inborn errors of immunity]. 成人先天性免疫缺陷的诊断与治疗
[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2023-01-01 DOI: 10.11406/rinketsu.64.772
Hirokazu Kanegane
{"title":"[Diagnosis and treatment of adult patients with inborn errors of immunity].","authors":"Hirokazu Kanegane","doi":"10.11406/rinketsu.64.772","DOIUrl":"https://doi.org/10.11406/rinketsu.64.772","url":null,"abstract":"<p><p>Primary immunodeficiency diseases (PID) are caused by abnormalities in molecules involved in the immune system, and there are nearly 500 genes associated with PID. The symptoms are not only susceptibile to infectious diseases but also to autoimmune diseases, malignancies, autoinflammatory diseases, and allergies. Thus, these diseases are considered inborn errors of immunity (IEI) rather than PID. IEI is typically thought to occur in childhood because IEI is associated with a genetic variant, but there are also several adult-onset IEIs. The same 10 warning signs used to diagnose IEI in children are used to diagnose the condition in adults as well, who are then given a definitive genetic diagnosis after a 4-step diagnostic process. In addition to prophylactic antimicrobial agents and immunoglobulin replacement therapy, allogeneic hematopoietic cell transplantation (HCT) is performed as a curative therapy in some patients with IEI. However, in adult patients with IEI, HCT may have to be stopped due to complications. Adult patients with IEI need to be promptly assessed for HCT, and HCT must be done before complications increase.</p>","PeriodicalId":6352,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"64 8","pages":"772-781"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10182683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2023-01-01 DOI: 10.11406/rinketsu.64.717
{"title":"","authors":"","doi":"10.11406/rinketsu.64.717","DOIUrl":"https://doi.org/10.11406/rinketsu.64.717","url":null,"abstract":"","PeriodicalId":6352,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"64 8","pages":"717"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10236205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Successful delivery using interferon α for molecular relapse of chronic myeloid leukemia after interruption of tyrosine kinase inhibitor]. [使用干扰素 α 成功治疗中断酪氨酸激酶抑制剂后分子复发的慢性髓性白血病]。
[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2023-01-01 DOI: 10.11406/rinketsu.64.102
Aya Shodai, Yukiko Tazaki, Natsuko Uchida, Tomonori Hamada, Rika Akahoshi, Takuya Ueno, Tomohisa Tabuchi, Naosuke Arima, Maiko Hayashida, Akihiko Arai, Daisuke Nakamura, Makoto Yoshimitsu, Hiroaki Kobayashi, Kenji Ishitsuka
{"title":"[Successful delivery using interferon α for molecular relapse of chronic myeloid leukemia after interruption of tyrosine kinase inhibitor].","authors":"Aya Shodai, Yukiko Tazaki, Natsuko Uchida, Tomonori Hamada, Rika Akahoshi, Takuya Ueno, Tomohisa Tabuchi, Naosuke Arima, Maiko Hayashida, Akihiko Arai, Daisuke Nakamura, Makoto Yoshimitsu, Hiroaki Kobayashi, Kenji Ishitsuka","doi":"10.11406/rinketsu.64.102","DOIUrl":"10.11406/rinketsu.64.102","url":null,"abstract":"<p><p>A tyrosine kinase inhibitor (TKI) was used to treat the patient, a 35-year-old woman who was diagnosed with chronic myeloid leukemia at the age of 22 years. Since a four-year deep molecular response (DMR) was obtained, spontaneous pregnancy was planned under TKI withdrawal. Even though her disease had advanced to MR2.0 at the time of pregnancy confirmation, 2 months from TKI cessation, interferon α therapy was initiated in light of the patient's history. Later, the patient reached MR3.0, gave birth to a healthy baby, and maintained MR3.0-4.0. TKI was resumed after about 6 months of breastfeeding. Treatment-free remission (TFR) is required for natural conception despite the teratogenicity and miscarriage risks associated with BCR::ABL1 TKIs. When planning a pregnancy, it is also necessary to take the patients' backgrounds, disease states, and medical history into account.</p>","PeriodicalId":6352,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"64 2","pages":"102-106"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9220906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Autoimmune hemolytic anemia complicated with acute kidney injury and tubulopathy due to hemoglobin casts]. 【自身免疫性溶血性贫血合并急性肾损伤和血红蛋白铸型引起的肾小管病变】。
[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2023-01-01 DOI: 10.11406/rinketsu.64.91
Junpei Rikitake, Seiji Kakiuchi, Ikumi Takagi, Mari Kagebayashi, Kodo Tomida, Toshiko Yoshida, Shigeo Hara, Nobuko Iwata, Toyomi Kamesaki
{"title":"[Autoimmune hemolytic anemia complicated with acute kidney injury and tubulopathy due to hemoglobin casts].","authors":"Junpei Rikitake,&nbsp;Seiji Kakiuchi,&nbsp;Ikumi Takagi,&nbsp;Mari Kagebayashi,&nbsp;Kodo Tomida,&nbsp;Toshiko Yoshida,&nbsp;Shigeo Hara,&nbsp;Nobuko Iwata,&nbsp;Toyomi Kamesaki","doi":"10.11406/rinketsu.64.91","DOIUrl":"https://doi.org/10.11406/rinketsu.64.91","url":null,"abstract":"<p><p>A 62-year-old male patient was admitted for close monitoring of anemia (hemoglobin level, 8.2 g/dl). Hemolytic anemia was observed; however, the direct antiglobulin test (DAT) result (standard tube method) was negative. Nevertheless, autoimmune hemolytic anemia (AIHA) was still suspected; therefore, a DAT (Colum method) and quantifying levels of red-blood-cell bound immunoglobulin G were performed, resulting in a definite diagnosis of warm AIHA. The patient also had an acute kidney injury (AKI) from the time of admission, which was poorly improved by supplemental fluids therapy alone. Therefore, renal biopsy was performed. Renal biopsy revealed acute tubular injury due to hemoglobin columns, and a diagnosed AKI caused by hemolysis due to AIHA. Following the definitive diagnosis of AIHA, the patient was treated with prednisolone, and after approximately 2 weeks, the anemia and nephropathy completely improved, which is maintained to this day. We report this case as a rare case of AKI induced by hemolysis of AIHA and a successful case of renal salvage by early administration of steroid.</p>","PeriodicalId":6352,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"64 2","pages":"91-96"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9220910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[An elderly patient with lymphoplasmacytic lymphoma successfully treated with low-dose tirabrutinib]. [低剂量替拉替尼治疗老年淋巴浆细胞性淋巴瘤1例成功]。
[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2023-01-01 DOI: 10.11406/rinketsu.64.245
Masato Yasumi, Kamma Shiraishi, Kimimori Kamijo, Tsuyoshi Kamae, Takahiro Karasuno
{"title":"[An elderly patient with lymphoplasmacytic lymphoma successfully treated with low-dose tirabrutinib].","authors":"Masato Yasumi,&nbsp;Kamma Shiraishi,&nbsp;Kimimori Kamijo,&nbsp;Tsuyoshi Kamae,&nbsp;Takahiro Karasuno","doi":"10.11406/rinketsu.64.245","DOIUrl":"https://doi.org/10.11406/rinketsu.64.245","url":null,"abstract":"<p><p>A 93-year-old woman was diagnosed with lymphoplasmacytic lymphoma (LPL) with circulating tumor cells in her peripheral blood after presenting with anemia. LPL progressed eight months later, with anemia worsening and tumor cells increasing to 66% of leukocytes. She began tirabrutinib at a low dose (80 mg daily: 17% of the standard dose) because she preferred to maintain her quality of life (QOL). Within three weeks, she was free of transfusion dependency and had a partial response with the disappearance of peripheral tumor cells. The dosage of tirabrutinib was increased to 240 mg daily because it was well tolerated. She has been on the treatment for 13 months with no adverse effects. Tirabrutinib, a highly selective Bruton's tyrosine kinase inhibitor, has been reported to have promising efficacy for LPL, but it also has a high incidence of dermatological toxicity, which may impair QOL. Low-dose tirabrutinib initiation may be effective and assist elderly patients with LPL in maintaining their QOL.</p>","PeriodicalId":6352,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"64 4","pages":"245-249"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9391448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Primary effusion lymphoma-like lymphoma transformed to diffuse large B-cell lymphoma]. [原发性积液淋巴瘤样淋巴瘤转化为弥漫性大b细胞淋巴瘤]。
[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2023-01-01 DOI: 10.11406/rinketsu.64.230
Naoto Ikeda, Takeshi Imao, Yuki Hisano, Takayuki Kamao, Masatoshi Uno, Takaaki Mizushima
{"title":"[Primary effusion lymphoma-like lymphoma transformed to diffuse large B-cell lymphoma].","authors":"Naoto Ikeda,&nbsp;Takeshi Imao,&nbsp;Yuki Hisano,&nbsp;Takayuki Kamao,&nbsp;Masatoshi Uno,&nbsp;Takaaki Mizushima","doi":"10.11406/rinketsu.64.230","DOIUrl":"https://doi.org/10.11406/rinketsu.64.230","url":null,"abstract":"<p><p>A rare kind of malignant lymphoma, called primary effusion lymphoma (PEL) is associated with human herpesvirus 8 (HHV-8), and characterized by lymphomatous effusion in the bodily cavities. Although the initial clinical presentation of primary effusion lymphoma-like lymphoma (PEL-LL) is similar to that of PEL, PEL-LL is HHV-8 negative and has a favorable prognosis. A PEL-LL diagnosis was made after an 88-year-old man was admitted to our hospital with a pleural effusion. His disease regressed after effusion drainage. He demonstrated disease progression to diffuse large B-cell lymphoma after two years and ten months. Our example demonstrates that aggressive B-cell lymphoma can develop from PEL-LL.</p>","PeriodicalId":6352,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"64 3","pages":"230-232"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9612092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2023-01-01 DOI: 10.11406/rinketsu.64.343
{"title":"","authors":"","doi":"10.11406/rinketsu.64.343","DOIUrl":"https://doi.org/10.11406/rinketsu.64.343","url":null,"abstract":"","PeriodicalId":6352,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"64 5","pages":"343"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9623651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Intestinal pneumatosis developed during the treatment of severe gastrointestinal graft-versus-host disease after cord blood transplantation]. [脐带血移植后严重胃肠道移植物抗宿主病治疗期间发生的肠道肺炎]。
[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2023-01-01 DOI: 10.11406/rinketsu.64.218
Yuma Kawamura, Nobuaki Fukushima, Tomoki Fujii, Masaya Numata, Makoto Ito, Shiori Morikawa, Miyo Goto, Akio Kohno, Kazutaka Ozeki
{"title":"[Intestinal pneumatosis developed during the treatment of severe gastrointestinal graft-versus-host disease after cord blood transplantation].","authors":"Yuma Kawamura,&nbsp;Nobuaki Fukushima,&nbsp;Tomoki Fujii,&nbsp;Masaya Numata,&nbsp;Makoto Ito,&nbsp;Shiori Morikawa,&nbsp;Miyo Goto,&nbsp;Akio Kohno,&nbsp;Kazutaka Ozeki","doi":"10.11406/rinketsu.64.218","DOIUrl":"https://doi.org/10.11406/rinketsu.64.218","url":null,"abstract":"<p><p>A 62-year-old female developed stage4 gastrointestinal graft-versus-host disease (GVHD) on day 109 following an allogeneic cord blood transplant for relapsed refractory angioimmunoblastic T-cell lymphoma. GVHD went into remission 4 weeks after receiving the steroid (mPSL 1 mg/kg), but abdominal bloating started to emerge at the same time. A diagnosis of intestinal pneumatosis was made on day 158 after a CT scan revealed submucosal and serosal pneumatosis in the entire colon, and intestinal pneumatosis was identified as the cause. Fasting and reducing steroid use have helped. the abdominal symptoms, and the pneumatosis disappeared on day 175. No more flare-ups occurred, and the steroid was successfully stopped. After allogeneic transplantation, intestinal pneumatosis is a rather uncommon complications. Its pathogenesis is thought to be influenced by GVHD or steroids. Treatments for the disease may be incompatible with one another, and the response in individual cases needs to be studied in detail.</p>","PeriodicalId":6352,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"64 3","pages":"218-223"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9626444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[In vitro production of red blood cells for future transfusion medicine]. [用于未来输血医学的红细胞的体外生产]。
[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2023-01-01 DOI: 10.11406/rinketsu.64.482
Ryo Kurita
{"title":"[In vitro production of red blood cells for future transfusion medicine].","authors":"Ryo Kurita","doi":"10.11406/rinketsu.64.482","DOIUrl":"https://doi.org/10.11406/rinketsu.64.482","url":null,"abstract":"<p><p>Large-scale in vitro red blood cell (RBC) production has been attempted in recent years. Potential cell sources for RBC production include hematopoietic stem/progenitor cells, pluripotent stem cells, and immortalized erythroid progenitor cell lines, which can induce enucleated RBCs with characteristics such as oxygen-carrying capacity and deformability. A phase I clinical study of cultured RBCs produced from hematopoietic stem/progenitor cells has revealed a similar in vivo half-life between cultured and native RBCs. Thus, the application of cultured RBCs in blood transfusion is gradually advancing. However, a single transfusion requires a large number of cells, unlike other cell therapies. Therefore, developing a method to mass-produce RBCs from a small culture volume at a low cost is important in the future. This review summarizes the current status and prospects concerning in vitro RBC production using each cell source, which can improve future transfusion medicine.</p>","PeriodicalId":6352,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"64 6","pages":"482-488"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9803682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信